Aquilo Capital Management, LLC In its 13F for Q4 2024 (holdings as of December 31, 2024, filed February 14, 2025), Aquilo Capital Management, LLC reported 13 stock positions worth $58.4 million . Its top holding was Arrowhead Pharmaceuticals (ARWR) at 22.8% of the portfolio, followed by Blueprint Medicines (BPMC, 19.4% ) and Kymera Therapeutics (KYMR, 12.6% ). Compared with Q3 2024, it opened 1 new position, sold out of 1, added to 6 and reduced 5. The biggest buy was Blueprint Medicines (BPMC, shares +4% ) and the biggest sale an exit from Merus (MRUS).
Location SAN FRANCISCO, CA
CIK 0001591986
Portfolio Value $58.4M (Q4 2024) Holdings 13 stocks · $58.4M Holdings quarter Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024
Stock % Of Portfolio ▼ Shares Held Total Value Change vs Q3 2024 ARWR Arrowhead Pharmaceuticals Inc. 707,589 $13.3M Reduce -11.1% BPMC Blueprint Medicines Corp. 129,600 $11.3M Add +4.0% KYMR Kymera Therapeutics Inc. 183,521 $7.4M Reduce -12.1% ARVN Arvinas Inc. 328,766 $6.3M Reduce -15.4% BCYC Bicycle Therapeutics PLC-ADR 221,911 $3.1M Add +22.0% PTGX Protagonist Therapeutics Inc. 76,592 $3.0M New RGNX Regenxbio Inc. 346,302 $2.7M Reduce -62.8% IMTX Immatics NV 373,902 $2.7M Add +12.1% SLN Silence Therapeutics PLC-ADR 367,214 $2.5M Add +15.8% ACET Adicet Bio Inc. 2,531,194 $2.4M No change DTIL Precision Biosciences Inc. 536,376 $2.0M Add +40.5% RPTX Repare Therapeutics Inc. 1,293,715 $1.7M Add +30.8% STRO Sutro Biopharma Inc. Com SHS 498 $916 Reduce -99.9%
Options reported separately and not counted above: AMGN calls ($6.5M), ARWR calls ($1.4M).
Portfolio Sells Q3 2024 → Q4 2024 Portfolio Sells quarter Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024
Stock Change vs Q3 2024 % Of Portfolio Change To Portfolio ▲ MRUS Merus NV Sold out 0.00% −6.63 RGNX Regenxbio Inc. Reduce -62.8% 4.58% −6.40 STRO Sutro Biopharma Inc. Com SHS Reduce -99.9% 0.00% −2.97 ARVN Arvinas Inc. Reduce -15.4% 10.79% +0.02 KYMR Kymera Therapeutics Inc. Reduce -12.1% 12.64% +1.52 ARWR Arrowhead Pharmaceuticals Inc. Reduce -11.1% 22.78% +5.43
Portfolio Buys Q3 2024 → Q4 2024 Portfolio Buys quarter Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024
Stock Change vs Q3 2024 % Of Portfolio Change To Portfolio ▼ BPMC Blueprint Medicines Corp. Add +4.0% 19.36% +6.39 PTGX Protagonist Therapeutics Inc. New 5.06% +5.06 BCYC Bicycle Therapeutics PLC-ADR Add +22.0% 5.32% +0.69 IMTX Immatics NV Add +12.1% 4.55% +0.27 DTIL Precision Biosciences Inc. Add +40.5% 3.50% −0.35 RPTX Repare Therapeutics Inc. Add +30.8% 2.90% −0.93 SLN Silence Therapeutics PLC-ADR Add +15.8% 4.33% −2.16
Options Activity Q3 2024 → Q4 2024 Security Type Change vs Q3 2024 Underlying Shares Value ▼ SPY SS SPDR S&P 500 ETF Trust-US put Sold out 75,000 $43.0Mbefore exit AMGN Amgen Inc. call New 25,000 $6.5M ARWR Arrowhead Pharmaceuticals Inc. call New 75,000 $1.4M
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings Quarter Positions 13F Reported Value Top Holdings Q3 2025 0 $0 Q2 2025 0 $0 Q1 2025 12 $37.1M BPMC, ARWR, PTGX, KYMR, DTIL Q4 2024 13 $58.4M ARWR, BPMC, KYMR, ARVN, BCYC Q3 2024 13 $88.8M ARWR, BPMC, KYMR, RGNX, ARVN Q2 2024 13 $103.7M ARWR, BPMC, ARVN, RGNX, KYMR Q1 2024 10 $133.4M ARWR, RGNX, BPMC, ARVN, KYMR